The extensive Champions TumorGraft® PDX bank includes a clinically relevant cohort of Prostate cancer models developed from primary and metastatic castration-resistant patients for translational preclinical studies.

These models include matched patient sample pre- and post-treatment in addition to extensive genomic characterization and in vivo response to androgen receptor inhibition that reflects the clinical response.

Through a recently awarded SBIR grant Champions will continue to expand the number and diversity of prostate cancer PDX models including from patients that progress on therapy and ethnic minorities.

The Champions TumorGraft prostate model cohort comprises of clinically-relevant, late stage and heavily pretreated tumors models.

Androgen Receptor/PSMA Expression in Champions TumorGraft® Prostate Cancer PDX Models

Models have been assessed via IHC for expression of Antigen Receptor and Prostate Specific Membrane Antigen (PSMA).
Oncoprint of specific mutational features in prostate cancer models. Common fusions in ERG and ETV and mutations affecting regulators of the PIK3CA-AKT pathway, microsatellite instability, and cell-cycle are highlighted in the post-treatment setting are highlighted.

**PDX Models Responses Reflect Clinical Outcomes: A Prostate Cancer Case Report (CTG-2440)**

- **Male, 74**
- **Stage I, Grade IV**
- **Gleason score = 6**

**Clinical response**
- Sustained reduction in tumor growth for 19 months
- High volume metastatic disease

**Additional Clinical Correlation Studies – Enzalutamide In Vivo Response**

Please visit championsoncology.com for access to the Champions TumorGraft database and updated information about Champions Oncology PDX models.